Tags

Type your tag names separated by a space and hit enter

Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism.
Clin Chem 2000; 46(8 Pt 1):1065-71CC

Abstract

BACKGROUND

Plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease. tHcy concentrations are partly determined by folate, cobalamin, and vitamin B(6) status, and methylenetetrahydrofolate reductase (MTHFR) and other flavoenzymes are important for the biotransformation of these vitamins. This motivates the investigation of the possible relationship between riboflavin status and tHcy.

METHODS

The study had a cross-sectional design and included 423 healthy blood donors, ages 19-69 years. We determined plasma tHcy, serum folate, serum cobalamin, serum creatinine, and MTHFR C677T genotype. In addition, we measured riboflavin and its two coenzyme forms, flavin mononucleotide and flavin adenine dinucleotide, in EDTA plasma by capillary electrophoresis and laser-induced fluorescence detection.

RESULTS

Riboflavin determined tHcy independently in a multiple linear regression model with adjustment for sex, age, folate, cobalamin, creatinine, and MTHFR genotype (P = 0.008). tHcy was 1.4 micromol/L higher in the lowest compared with the highest riboflavin quartile. The riboflavin-tHcy relationship was modified by genotype (P = 0.004) and was essentially confined to subjects with the C677T transition of the MTHFR gene.

CONCLUSIONS

Plasma riboflavin is an independent determinant of plasma tHcy. Studies on deficient populations are needed to evaluate the utility of riboflavin supplementation in hyperhomocysteinemia.

Authors+Show Affiliations

LOCUS for Homocysteine and Related Vitamins, University of Bergen, Armauer Hansens Hus, N-5021 Bergen, Norway. steiner.hustad@farm.uib.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10926884

Citation

Hustad, S, et al. "Riboflavin as a Determinant of Plasma Total Homocysteine: Effect Modification By the Methylenetetrahydrofolate Reductase C677T Polymorphism." Clinical Chemistry, vol. 46, no. 8 Pt 1, 2000, pp. 1065-71.
Hustad S, Ueland PM, Vollset SE, et al. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem. 2000;46(8 Pt 1):1065-71.
Hustad, S., Ueland, P. M., Vollset, S. E., Zhang, Y., Bjørke-Monsen, A. L., & Schneede, J. (2000). Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clinical Chemistry, 46(8 Pt 1), pp. 1065-71.
Hustad S, et al. Riboflavin as a Determinant of Plasma Total Homocysteine: Effect Modification By the Methylenetetrahydrofolate Reductase C677T Polymorphism. Clin Chem. 2000;46(8 Pt 1):1065-71. PubMed PMID: 10926884.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. AU - Hustad,S, AU - Ueland,P M, AU - Vollset,S E, AU - Zhang,Y, AU - Bjørke-Monsen,A L, AU - Schneede,J, PY - 2000/8/6/pubmed PY - 2000/8/29/medline PY - 2000/8/6/entrez SP - 1065 EP - 71 JF - Clinical chemistry JO - Clin. Chem. VL - 46 IS - 8 Pt 1 N2 - BACKGROUND: Plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease. tHcy concentrations are partly determined by folate, cobalamin, and vitamin B(6) status, and methylenetetrahydrofolate reductase (MTHFR) and other flavoenzymes are important for the biotransformation of these vitamins. This motivates the investigation of the possible relationship between riboflavin status and tHcy. METHODS: The study had a cross-sectional design and included 423 healthy blood donors, ages 19-69 years. We determined plasma tHcy, serum folate, serum cobalamin, serum creatinine, and MTHFR C677T genotype. In addition, we measured riboflavin and its two coenzyme forms, flavin mononucleotide and flavin adenine dinucleotide, in EDTA plasma by capillary electrophoresis and laser-induced fluorescence detection. RESULTS: Riboflavin determined tHcy independently in a multiple linear regression model with adjustment for sex, age, folate, cobalamin, creatinine, and MTHFR genotype (P = 0.008). tHcy was 1.4 micromol/L higher in the lowest compared with the highest riboflavin quartile. The riboflavin-tHcy relationship was modified by genotype (P = 0.004) and was essentially confined to subjects with the C677T transition of the MTHFR gene. CONCLUSIONS: Plasma riboflavin is an independent determinant of plasma tHcy. Studies on deficient populations are needed to evaluate the utility of riboflavin supplementation in hyperhomocysteinemia. SN - 0009-9147 UR - https://www.unboundmedicine.com/medline/citation/10926884/Riboflavin_as_a_determinant_of_plasma_total_homocysteine:_effect_modification_by_the_methylenetetrahydrofolate_reductase_C677T_polymorphism_ L2 - http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=10926884 DB - PRIME DP - Unbound Medicine ER -